Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839538 | 0.91 | ACHE (0.61) | ACHETSHRFAAHEPHX1 | |
| SCHEMBL11338236 | 0.91 | ACHE (0.61) | ACHETSHRFAAHEPHX1 | |
| SCHEMBL23111386 | 0.89 | TSHR (0.46) | ACHETSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29939 | 0.89 | ACHE (0.58) | ACHEFAAHEPHX1 | |
| SCHEMBL1486852 | 0.86 | ACHE (0.55) | ACHETSHRFAAHEPHX1 | |
| SCHEMBL28255343 | 0.86 | TSHR (0.42) | ACHETSHRALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL8928159 | 0.83 | ACHE (0.48) | ACHETSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL21570876 | 0.83 | TSHR (0.48) | ACHETSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4458944 | 0.82 | ACHE (0.47) | ACHETSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8865477 | 0.82 | TSHR (0.41) | ACHETSHRALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697785-B2 | N-allyl carbamate compounds and use thereof, in particular in radiation-curing coatings | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2014-04-15 | — | — | US | disclosed |
| US-20120296021-A1 | N-ALLYL CARBAMATE COMPOUNDS AND USE THEREOF, IN PARTICULAR IN RADIATION-CURING COATINGS | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V (DE) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296021-A1 | N-ALLYL CARBAMATE COMPOUNDS AND USE THEREOF, IN PARTICULAR IN RADIATION-CURING COATINGS | C9, ERCC1, C5 | ACHE 1557/4885TSHR 1559/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.